The acquisition adds a clinical-stage prostate cancer therapy and a novel RIPTAC platform aimed at improving precision targeting and overcoming treatment resistance in solid tumors.

Johnson & Johnson terminated its Phase 2b trial for JNJ-5939 after an interim analysis showed the drug failed to meet high-bar efficacy standards for treatment.

Johnson & Johnson MedTech can create high-fidelity digital twins using NVIDIA Omniverse libraries and build applications that simulate how the system may perform in the operating room and inside a patient.

The new tissue-sparing system enables day-one post-op mobility, enhances joint visualization, and supports outpatient surgery as shoulder replacements grow 7.3% annually.

Johnson & Johnson introduces its first forward IVL platform with a distal emitter, delivering 120 shockwaves to safely treat calcified lesions in peripheral artery disease patients.

The VIRTUGUIDE Software utilizes AI technology to automatically analyze the patient’s anatomy based on provided CT or X-ray images.

Johnson & Johnson receives U.S. FDA Priority Review for TAR-200, an innovative drug delivery system for high-risk non-muscle invasive bladder cancer.

Johnson & Johnson's sNDA submission for CAPLYTA, cites 63% relapse reduction; expands industry’s broadest schizophrenia treatment portfolio for adults.

VOLT plating systems address rising wrist and shoulder fracture cases with advanced locking tech, optimized plate design, and expanded implant options.

ETHICON's 3D Reloads and Gripping Surface Technology minimize tissue complexities and leaks/bleeds, with this advanced stapling exclusively for OTTAVA Robotic Surgical System.